scholarly journals Prevalence of Oral and Pharyngeal Cancers and the Relationship Between Tumour Size and Lymph Node Metastases in Oral Cancer.

2021 ◽  
Author(s):  
Abdullah Omar ◽  
Mohammad Rmman ◽  
Madiha Al Hafi ◽  
Mohammad Sadek Al-Masalmeh ◽  
Louei Darjazini Nahas
Keyword(s):  
Lymph Node ◽  
Oral Cancer ◽  
Tumour Size ◽  
Nasopharyngeal Cancer ◽  
Chief Complaint ◽  
Histological Type ◽  
Pharyngeal Cancer ◽  
Lower Lip ◽  
Oral And Pharyngeal Cancer ◽  
The Relationship

Abstract Background: the study aimed at studying the incidence and prevalence rates of oral and pharyngeal cancer and their distribution according to gender, tumour size, histological type and chief complaint. We also tackled the relationship between the tumour size and the metastasis to the regional lymph nodes.Materials and Methods: This cohort retrospective study was done in Al-Mouasat hospital from January 2017 to June 2020. The population included patients with oral or pharynx cancer who were admitted to the Ear, Nose, Throat department.Results: The total participants were 96 cases. The median age was 57 year. The most common tumour location was oral tumour 58.3%, and the most common chief complaint about oral tumour was mass by 62.5%. while nasopharynx cases most commonly came with neck mass 68.2%. 50% was the percentage of dysphagia that was the most common complaint. Squamous cell carcinoma (SCC) was the most common histologic type < 90% of the oral, oropharynx, and hypopharynx cases. About the classification of the tumour due to its subsite 33.9% of the oral cases were in lip and especially the lower one. Whereas, oropharynx most frequent tumour site was the tonsil (50%). we found statistical evidence for the relationship between the tumour size (T) and the metastasis to the regional lymph node (N) in oral cancer.Conclusion: Oral and pharyngeal cancer is a very important issue. And according to our paper, the most frequent cancer was oral cancer and especially lower lip tumour. oral cancer presents with mass. whereas, the nasopharyngeal cancer presentation was neck mas. The most common histological type was SCC. And we reached a relationship between the T and N in oral cancer

Oral and Pharyngeal Cancer: Combined Approach for Multimodal Therapy

1983 ◽  
Vol 69 (6) ◽  
pp. 563-566 ◽  
Author(s):  
Massimo Fazio ◽  
Fausto Badellino ◽  
Gian Luca Sannazzari ◽  
Vittorio Vercellino ◽  
Mario Airoldi ◽  
...  
Keyword(s):  
Lymph Node ◽  
Complete Remission ◽  
Cancer Patients ◽  
Multimodal Therapy ◽  
Combined Approach ◽  
Pharyngeal Cancer ◽  
Chi Square ◽  
Actuarial Survival ◽  
Oral And Pharyngeal Cancer ◽  
Chi Square Test

Five-year results in 60 oral and pharyngeal cancer patients treated with combined apporach chemoradiotherapy (39 patients) and chemoradiotherapy plus lymph node surgery (21 patients) are reported. Complete remission (CR) was achieved in 16/39 (41%) patients treated with chemoradiotherapy alone, and in 16/21 (76%) patients who had chemoradiotherapy plus surgery. The number of CR was statistically (chi-square test) higher (p < 0.025) in the second group. The 5-year actuarial survival was 39.7% in the group of patients treated with chemoradiotherapy plus surgery. After 5 years 53% of the patients who reached CR are living free of disease in the first group and 76% in the second group.

scholarly journals Expression of a Splice Variant of CYP26B1 in Betel Quid-Related Oral Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Ping-Ho Chen ◽  
Ka-Wo Lee ◽  
Cheng-Chieh Hsu ◽  
Jeff Yi-Fu Chen ◽  
Yan-Hsiung Wang ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Splice Variant ◽  
Full Length ◽  
Betel Quid ◽  
Human Gingival Fibroblast ◽  
Cancer Tissue ◽  
Gingival Fibroblast ◽  
Dependent Manner ◽  
Pharyngeal Cancer ◽  
Oral And Pharyngeal Cancer

Betel quid (BQ) is a psychostimulant, an addictive substance, and a group 1 carcinogen that exhibits the potential to induce adverse health effects. Approximately, 600 million users chew a variety of BQ. Areca nut (AN) is a necessary ingredient in BQ products. Arecoline is the primary alkaloid in the AN and can be metabolized through the cytochrome P450 (CYP) superfamily by inducing reactive oxygen species (ROS) production. Full-length CYP26B1 is related to the development of oral pharyngeal cancers. We investigated whether a splice variant of CYP26B1 is associated with the occurrence of ROS related oral and pharyngeal cancer. Cytotoxicity assays were used to measure the effects of arecoline on cell viability in a dose-dependent manner.In vitroandin vivostudies were conducted to evaluate the expression of the CYP26B1 splice variant. The CYP26B1 splice variant exhibited lower expression than did full-length CYP26B1 in the human gingival fibroblast-1 and Ca9-22 cell models. Increased expression of the CYP26B1 splice variant was observed in human oral cancer tissue compared with adjacent normal tissue, and increased expression was observed in patients at a late tumor stage. Our results suggested that the CYP26B1 splice variant is associated with the occurrence of BQ-related oral cancer.

scholarly journals The Epidemiological Trend of Oral Carcinoma in Eastern Europe

2019 ◽  
Vol 70 (8) ◽  
pp. 2917-2922
Author(s):  
Ramona Camelia Rumel ◽  
Laura Cristina Rusu ◽  
Pusa Nela Gaje ◽  
Ramona Amina Popovici ◽  
Marius Raica
Keyword(s):  
Oral Cancer ◽  
World Health ◽  
Pharyngeal Cancer ◽  
East Europe ◽  
Epidemiological Trend ◽  
Incidence And Mortality ◽  
Oral And Pharyngeal Cancer ◽  
Specific Mortality ◽  
Health Organization ◽  
Very High

Oral and pharyngeal cancer is estimated by World Health Organization (WHO) to be the eighth most common cancer worldwide with signi�cant regional variation with increasing and decreasing incidence trend. The aim of the study was to evaluate the oral cancer epidemiological trend, incidence and mortality in Central and East Europe (CEE), and to compare the incidence of oral cancer with other regions from the world. The analyzed data was from NORDCAN and GLOBOCAN, using ASR (age- standardize rate) incidence and mortality overall and by sexes. The incidence of oral and pharyngeal cancer is higher in CEE than the global incidence. This is in accord with specific mortality from oral and pharyngeal cancer that is higher in CEE than the regions other submitted to the current evaluation. The incidence of oral cancer is very high at man, especially in Hungary, which is the most affected from oral cancer from CEE.

Disparities in Optimal Treatment of Oral and Pharyngeal Cancer by Ethnicity and Smoking Status

2020 ◽  
Vol 22 ◽  
Author(s):  
Hannah Fechtel
Keyword(s):  
Smoking Status ◽  
Optimal Treatment ◽  
Racial Groups ◽  
Pharyngeal Cancer ◽  
Cancer Data ◽  
Oral And Pharyngeal Cancer ◽  
Treatment Plans ◽  
Race Ethnicity ◽  
To Receive ◽  
The Relationship

Oral and Pharyngeal Cancer (OPC) is a deadly cancer with complex treatment plans and outcomes. In practice, surgery followed by radiation or chemotherapy is considered the “optimal treatment” associated with better OPC survival. However, not all OPC patients receive the optimal treatment. Prior research has documented that survival varies by smoking status and ethno-racial groups, but little is known about the relationship between a patient’s smoking status, ethnicity, and the choices they make about cancer treatment post diagnosis. To shed light on this under-studied issue, data from the Florida Cancer Data System were analyzed. A logit model was built with the response variable treatment pattern arranged into three levels: surgery only (reference), surgery followed by radiation or chemotherapy, and other treatment types. The predictors included smoking status, race-ethnicity, smoking by race-ethnicity interaction, health insurance, age at diagnosis, gender, and marital status. Overall, the odds of receiving optimal treatment for Non-Hispanic Whites  and Non-Hispanic Blacks are 29%-34% (p<0.001) greater than the odds of optimal treatment for Hispanics. One significant smoking by race-ethnicity interaction was found between Non-Hispanic Blacks and current smoking status, making Non-Hispanic Blacks who currently smoke less likely to receive optimal treatment than those who do not smoke.

scholarly journals Lymph node metastasis in lower lip squamous cell carcinoma in relation to tumour size, histologic variables and p27Kip1 protein expression

Oral Oncology ◽  
2004 ◽  
Vol 40 (1) ◽  
pp. 92-98 ◽  
Author(s):  
Vito Rodolico ◽  
Elisa Barresi ◽  
Roberto Di Lorenzo ◽  
Vincenza Leonardi ◽  
Pietro Napoli ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Protein Expression ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumour Size ◽  
Lower Lip ◽  
P27kip1 Protein ◽  
Node Metastasis

Baseline data of oral and pharyngeal cancer before introducing an oral cancer prevention campaign in Germany

2015 ◽  
Vol 43 (3) ◽  
pp. 360-366 ◽  
Author(s):  
Katrin Hertrampf ◽  
Nora Eisemann ◽  
Jörg Wiltfang ◽  
Ron Pritzkuleit ◽  
Hans-Jürgen Wenz ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Cancer Prevention ◽  
Baseline Data ◽  
Pharyngeal Cancer ◽  
Prevention Campaign ◽  
Oral And Pharyngeal Cancer

Early detection of oral cancer in Portugal: The experience of UMEMD.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13039-e13039
Author(s):  
Fernanda Estevinho ◽  
Margarida Gouveia ◽  
Marta Costa ◽  
Sara Moura ◽  
João Sérgio Neves ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Early Diagnosis ◽  
Cancer Diagnosis ◽  
Pharyngeal Cancer ◽  
Cancer History ◽  
Oral Cancers ◽  
The North ◽  
Oral And Pharyngeal Cancer ◽  
The University ◽  
Suspicious Lesions

e13039 Background: Oral and pharyngeal cancer is the 11th most common malignancy worldwide. Although the oral cavity is a potentially accessible site for examination, up to 50% of oral cancers are detected at advanced stage. The Mobile Unit of Stomatology and Dental Medicine (UMEMD) of the Portuguese League Against Cancer (LPCC) and of the Portuguese Association of Hospital Dental Medicine (APMDH) has developed oral cancer early diagnosis consultations. This consultations were performed by a team of 50 doctors specialized in oral cancer diagnosis. Once a month the team of UMEMD went to a different region of the North of Portugal. Early oral cancer diagnosis consultations were also performed twice a week at the Portuguese League Against Cancer at Oporto.We present the experience of UMEMD in the early diagnosis consultation of oral cancer, since its foundation in August 2012 until the end of 2016. Methods: We performed a retrospective evaluation of medical records of patients observed in the early diagnosis consultation of oral cancer of UMEMD between August 2012 and December 2016. We assessed the demographic characteristics, risk factors, cancer history, likely diagnosis and the referral of patients. Results: 6,231 new patients were observed; median age of patients was 63 years-old [1;102], 93 patients were younger than 18 years-old. There was information about smoking habits of the majority of patients n = 4,521(72.6%): 597(9.6%) were smokers and 653(10.5%) former smokers. 228 (3.6%) patients had previous cancer. We detected: 963 lesions (15.5%); the majority of the lesions were at the tongue n = 263 (4.2%).The patients with suspicious lesions (n = 638; 10.2%) were referred to: Portuguese Institute of Oncology of Oporto: n = 146 (2.3%); Faculty of Dental Medicine of the University of Oporto: n = 353 (5.7%); Physicians at other hospitals: n = 139 (2.2%). Conclusions: Consultations for oral cancer early diagnosis performed by an experienced team has enabled the detection of suspicious lesions in 10.2% of the patients. Cooperation with other institutions, through protocols, allowed the referral and early treatment of these patients.

scholarly journals The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis

2020 ◽  
Vol 12 ◽  
pp. 175883592095835
Author(s):  
Wei-Ping Li ◽  
Hong-Fei Gao ◽  
Fei Ji ◽  
Teng Zhu ◽  
Min-Yi Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Tumour Size ◽  
Male Breast ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Chemotherapy Group

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I–III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy. Methods: Male breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan–Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival. Results: We enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups ( p < 0.001 for OS and p = 0.128 for BCSS, respectively). Compared with the non-chemotherapy group, the chemotherapy group had a higher 4-year OS rate (97.5% versus 95.2%, p < 0.001), while 4-year BCSS was similar (98% versus 98.8%, p = 0.128). The chemotherapy group had longer OS than the non-chemotherapy group among HR+, HER2–, tumour size >2 cm, lymph node-positive male breast cancer patients ( p < 0.05). Regardless of tumour size, there were no differences in OS or BCSS between the chemotherapy and non-chemotherapy cohorts for lymph node-negative patients (OS: p > 0.05, BCSS: p > 0.05). Adjuvant chemotherapy showed no significant effects on both OS and BCSS in patients with stage I (OS: p = 0.100, BCSS: p = 0.858) and stage IIA breast cancer (OS: p > 0.05, BCSS: p > 0.05). Conclusion: For stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.

scholarly journals Rare lung cancers—Primary pulmonary leiomyosarcoma: A case report

2021 ◽  
Author(s):  
Laurenz Nagl ◽  
Andreas Seeber ◽  
Gerlig Widmann ◽  
Katja Schmitz ◽  
Herbert Maier ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Tumour Size ◽  
Lymph Node Status ◽  
R0 Resection ◽  
Interdisciplinary Management ◽  
Curative Surgery ◽  
Lung Cancers ◽  
Tumour Control ◽  
Complete Tumour

SummaryPrimary pulmonary sarcomas (PPS) are rare mesenchymal lung cancers, which do not present clinically or radiological different to lung carcinomas. Definite PPS diagnosis can only be made by histological analysis and detailed staging examinations in order to exclude a secondary pulmonary malignancy such as metastatic soft tissue sarcoma or another solid tumour. Here we present the case of a 66-year-old woman with a pulmonary mass infiltrating the diaphragm and the mediastinal adipose tissue, which was identified as leiomyosarcoma. The patient received curative surgery with complete tumour R0 resection. The prognosis of PPS is defined by tumour size, lymph node status and histological grading. Surgery is the mainstay of therapy and there is no definitive indication for adjuvant therapy for R0-resected and lymph-node-negative patients like in our case. However, multimodal therapy approaches such as (neo)adjuvant chemo- and radiotherapy can contribute to improving locoregional tumour control, which is the most important prognostic factor. With our case report we want to raise awareness for pulmonary sarcomas as a relevant proportion of rare lung cancers which have to be kept in mind during the differential diagnosis. Moreover, we aim to discuss the complex and individual interdisciplinary management.

Sign in / Sign up

Export Citation Format

Share Document